The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Biotechnology
Sailong Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.96% CNY10.42
America/New_York / 6 mai 2024 @ 01:43
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 833.92 mill |
| EPS: | 0.0500 |
| P/E: | 208.40 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 176.00 mill |
| Avg Daily Volume: | 8.63 mill |
| RATING 2024-05-06 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 5.81x |
| Company: PE 208.40 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 7.11x |
| Company: PE 208.40 | industry: PE 29.29 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
CNY 9.87 - 10.99 ( +/- 5.41%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY10.42 (2.96% ) |
| Volume | 2.60 mill |
| Avg. Vol. | 8.63 mill |
| % of Avg. Vol | 30.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002898.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002898.SZ
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium products. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding medicine, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.